FGF21 and its analogues activate FGFR1c/β-Klotho signaling, promoting fatty acid oxidation, WAT browning, and PGC-1α-driven thermogenesis, with early trials showing improvements in lipid profiles and hepatic steatosis. Here, PPARGC1A is linked to fatty liver disease.